Critique of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST): Flaws in CREST and its Interpretation  by Paraskevas, K.I. et al.
REVIEWCritique of the Carotid Revascularization Endarterectomy versus Stenting
Trial (CREST): Flaws in CREST and its Interpretation
K.I. Paraskevas a, D.P. Mikhailidis b, C.D. Liapis c, F.J. Veith d,*
a Department of Vascular Surgery, Red Cross Hospital, Athens, Greece
b Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital Campus, University College London Medical School, University College
London (UCL), London, UK
c Department of Vascular Surgery, “Attiko” University Hospital, Athens University Medical School, Athens, Greece
d Divisions of Vascular Surgery, The Cleveland Clinic and New York University Langone Medical Center, New York, USA* Co
Bronx,
E-ma
1078
Surger
httpThe Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) has been used to support the
equivalence of carotid artery stenting (CAS) and carotid endarterectomy (CEA) in the treatment of carotid
stenosis in both symptomatic and asymptomatic patients. This inclusion of two different forms of the disease
decreased the power and signiﬁcance of the CREST results and weakened the trial. Other ﬂaws in CREST were the
equal weighting of mostly minor myocardial infarctions (MIs) with strokes and death in the peri-procedural,
composite ‘end’ point, but not in the 4-year, long-term ‘end’ point. Although CAS was associated with 50% fewer
peri-procedural MIs compared with CEA, there were >2.5-fold more MIs after CAS than CEA at 4 years. The 4-
year MI rate, however, was not a component of the primary ‘end’ point. Additionally, although the initial CREST
report indicated that there was no difference in the outcomes of CAS and CEA according to symptomatic status
or sex, subsequent subgroup analyses showed that CAS was associated with signiﬁcantly higher stroke and death
rates than CEA in symptomatic patients, in females and in individuals 65 years of age. The present article will
examine these and other ﬂaws and the details of CREST’s results derived from the trial’s preplanned subanalyses
to show why the claims that CREST demonstrates equivalence of the two therapeutic procedures are unjustiﬁed.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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versus Stenting Trial (CREST) investigators reported that the
composite ‘end’ point of peri-procedural stroke, myocardial
infarction (MI) or death or any ipsilateral stroke within 4
years after randomisation did not differ in patients with
carotid artery stenosis (n ¼ 2502) undergoing carotid artery
stenting (CAS; n ¼ 1262) or carotid endarterectomy (CEA;
n ¼ 1240) (7.2% vs. 6.8%, respectively; hazard ratio (HR)
with CAS: 1.11; 95% conﬁdence interval (CI): 0.81e1.51;
p ¼ 0.51).1 CREST included both symptomatic (n ¼ 1321)
and asymptomatic (n ¼ 1181) patients.2 Of these, 872
(34.9%) patients were females and 1630 (65.1%) were
males.3 According to the initial CREST report,1 “there was
no differential treatment effect with regard to the primary
end-point according to symptomatic status (p ¼ 0.84) or sex
(p ¼ 0.34).”
Approximately 5 months later, the American Heart Asso-
ciation (AHA) together with the American Stroke Association
(ASA) put forth a guideline indicating that CAS is an ‘alterna-
tive’ to CEA for the management of symptomatic carotid
stenosis.4 Unfortunately, this AHA/ASA guideline4 did notrresponding author. F.J. Veith, 4455 Douglas Avenue, Apt 11 E,
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://dx.doi.org/10.1016/j.ejvs.2013.03.014consider or include the International Carotid Stenting Study
(ICSS).5,6 The reason given was that “the timing of publication
of ICSS precluded its incorporation into this version of the
Guidelines. Publication of 2011 Guidelines was ultimately
delayed in order to include the results of CREST”.7 However,
ICSS5 was published 4 months before CREST.1
The AHA, the ASA and 12 other important Societies
subsequently published a new set of guidelines,8 this time
also including ICSS.5 Despite the consideration of ICSS,5
however, these guidelines once again recommended CAS
as an ‘alternative’ to CEA in symptomatic patients.8 Addi-
tionally, this guideline recommended that prophylactic CAS
might be considered in selected asymptomatic patients, but
its effectiveness compared with current best medical
treatment (BMT) alone for these patients was recognised as
not being well established (Class IIb).8 As the AHA/ASA
recommendations4,8 were largely based on the initial
CREST1 report, they differ substantially from the guidelines
published by other societies (e.g., the U.S. and the Austra-
lian/New Zealand Societies for Vascular Surgery).9
CREST1 and the AHA/ASA guidelines4,8 have prompted
many to conclude that CAS and CEA are generally equivalent
and to promote wider use of CAS in standard- and low-risk
symptomatic and asymptomatic patients with carotid
stenosis.10,11 The present article will make the case that the
detailed data fromCREST, including its subgroup analyses,2,3,12
do not support the general equivalence of CAS and CEA. This
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patients,2 females3 and patients aged 65 years or more.12 The
present case suggesting a wider role for CAS in the manage-
ment of asymptomatic patients will also be disputed.
FLAWS IN CREST AND ITS INTERPRETATION
Inclusion of asymptomatic patients
CREST began in December 2000 and initially included only
symptomatic patients.1 Due to a lag in recruitment of
symptomatic patients, in 2005 the CREST investigators
began enrolling asymptomatic individuals. When the trial
stopped enrolling patients in July 2008, it included 1262
CAS and 1240 CEA patients.1 Of these, 47.1% of CAS and
47.3% of CEA patients were asymptomatic.1
In a report of the early results of CREST,13 it is stated that
almost two-thirds of the CAS population (789 of 1262
patients; 62.5%) had already been enrolled in less than the
ﬁrst 3.5 years of the study (December 2000 to 31 March
2004). All these patients were symptomatic. It would be
interesting to know why the CREST investigators decided
that they could not enrol the remaining 473 (37.5%)
symptomatic patients in the remaining 4.5 years of the
study (1 April 2004 to July 2008). If almost two-thirds of the
CAS population had already been enrolled by 31 March
2004, it is puzzling that the percentage of asymptomatic
CAS patients in the ﬁnal report1 was as high as 47.1%.
Inclusion of MIs in the primary ‘end’ point
The inclusion of MIs as an ‘end’ point of equal weight to
stroke and death should be viewed with some concern.
First, no other randomised controlled trial comparing CAS
with CEA has included MIs as a primary ‘end’ point (besides
CREST1 and SAPPHIRE (Stenting and Angioplasty With
Protection in Patients at High Risk for Endarterectomy)14).Table 1. Primary end-point, components of the primary end-point and
CAS (n ¼ 1262
Nr. of pts (%)
Periprocedural death 9 (0.7%)
Any periprocedural stroke 52 (4.1%)
Periprocedural major ipsilateral strokes 11 (0.9%)
Periprocedural minor ipsilateral strokes 37 (2.9%)
Periprocedural myocardial infarction 14 (1.1%)
Any periprocedural stroke or postprocedural
ipsilateral stroke
52 (4.1%)
4-year death (including periprocedural period) 94 (7.5%)
Any stroke (periprocedural period þ 4-year
follow-up)
105 (10.2%)
Major ipsilateral stroke (periprocedural
period þ 4-year follow-up)
16 (1.4%)
Minor ipsilateral stroke (periprocedural
period þ 4-year follow-up)
52 (4.5%)
Myocardial infarction (periprocedural period þ 4-
year follow-up)
72 (6.2%)
Primary end-point (any periprocedural stroke,
myocardial infarction or death or 4-year
postprocedural ipsilateral stroke)
85 (7.2%)
CAS: carotid artery stenting; pts: patients; nr.: number; CEA: carotid eThe purpose of CAS and CEA is to prevent strokes (as well as
death resulting from strokes), not MIs. As CAS is a minimally
invasive procedure, it is not a surprise that it is associated
with fewer peri-procedural MIs compared with CEA. Inter-
estingly, although CAS was associated with 50% fewer peri-
procedural MIs compared with CEA (14 vs. 28, respectively),
there were >2.5-fold more MIs after CAS than CEA at 4
years (excluding peri-procedural MIs, 58 vs. 22, respectively;
Table 1). The 4-year MI rate, however, was not a component
of the primary ‘end’ point.
Second, in CREST “myocardial infarction was deﬁned by
a creatine kinase MB or troponin level that was twice the
upper limit of the normal range or higher according to the
centre’s laboratory, in addition to either chest pain or
symptoms consistent with ischemia or ECG evidence of
ischemia, including new ST-segment depression or elevation
of more than 1 mm in two or more contiguous leads
according to the core laboratory”.1 This is an unusual deﬁ-
nition of an MI. Besides the fact that no speciﬁc duration for
the ‘chest pain’ is provided, ‘chest pain’ is a symptom of
myocardial ischaemia, not a synonym of infarction. It is
incorrect to consider any ‘chest pain’ as an MI. Stable
angina pectoris also produces chest pain. The same applies
to the electrocardiography (ECG) and biochemical charac-
teristics listed by the CREST investigators. An ST-depression
of >1 mm is ‘ECG evidence of ischaemia’,1 not an MI.
Third, it is inappropriate to group together as the
‘primary ‘end’ point’ a major stroke or death with a minor
MI. The effect an MI has on the patient’s quality of life
cannot be equated with the effects of a stroke (even
a minor one). By use of the Medical Outcomes Study 36-
Item Short-Form Health Survey (SF-36), it was demon-
strated in CREST that major and minor strokes had
a considerable effect on the patient’s physical health at 1
year, whereas the effect of peri-procedural MI was less.1other events in CREST.1
pts) CEA (n ¼ 1240 pts)
Nr. of pts (%)
HR for CAS vs CEA
(95% CI)
p
4 (0.3%) 2.25 (0.69e7.30) 0.18
29 (2.3%) 1.79 (1.14e2.82) 0.01
4 (0.3%) 2.67 (0.85e8.40) 0.09
17 (1.4%) 2.16 (1.22e3.83) 0.009
28 (2.3%) 0.50 (0.26e0.94) 0.03
29 (2.3%) 1.79 (1.14e2.82) 0.01
83 (6.7%) 1.12 (0.83e1.51) 0.45
75 (7.9%) 1.40 (1.04e1.89) 0.03
6 (0.5%) 2.56 (1.00e6.54) 0.05
36 (3.5%) 1.43 (0.94e2.19) 0.10
50 (4.7%) 1.44 (1.00e2.06) 0.049
76 (6.8%) 1.11 (0.81e1.51) 0.51
ndarterectomy; HR: hazard ratio; CI: conﬁdence interval.
Table 2. Routine drug treatment administered to patients
undergoing CEA or CAS in CREST.1 This information is listed in
Table 1 of the CREST1 Supplementary Appendix (available at:
http://www.nejm.org/doi/suppl/10.1056/NEJMoa0912321/suppl_
ﬁle/nejmoa0912321_appendix.pdf).
CAS patients
- At least 48 hours before CAS, patients
received aspirin 325 mg twice daily and
clopidogrel 75 mg twice daily. Instead of
clopidogrel, patients could receive
ticlopidine 250 mg twice daily.
- When CAS was scheduled within 48 hours
after randomization, patients received
650 mg aspirin and 450 mg clopidogrel 4
or more hours before the procedure.
- After CAS, patients received 325 mg
aspirin once or twice daily for 30 days
plus either 75 mg/day clopidogrel twice
daily for 4 weeks or 250 mg ticlopidine
twice daily for 4 weeks.
- The continuation of 325 mg/day aspirin
for >4 weeks after the procedure was
recommended for all CAS patients.
CEA patients
- At least 48 hours before CEA, patients
received aspirin 325 mg/day.
- Following CEA, patients remained on
aspirin 325 mg/day indeﬁnitely (at least
1 year).
- For those patients intolerant to this dose,
acceptable alternatives included
clopidogrel 75 mg/day, aspirin 81 mg/day,
ticlopidine 250 mg twice daily or aspirin
and extended-release dipyridamole twice
daily.
CEA: carotid endarterectomy; CAS: carotid artery stenting.
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mental health at 1 year.1 As with the enrolment of
asymptomatic patients, the inclusion of MIs as equivalent
adverse events with stroke and death in the primary ‘end’
point could have improved the CAS composite outcomes.
The initial CREST1 report mentioned that there was no
difference in the primary ‘end’ point between the two
groups within the complete cohort (thus including both
symptomatic and asymptomatic patients). Further analysis,
however, showed that CAS was associated with a >2-fold
higher risk of peri-procedural death, an almost 2-fold
increased risk for any peri-procedural stroke, a >2.5-fold
increased risk for major ipsilateral stroke and a >2-fold
increased risk for minor ipsilateral stroke (Table 1). By
contrast, CREST patients undergoing CAS suffered 50% fewer
MIs compared with those undergoing CEA. The difference in
MIs balanced the difference in strokes and produced the
apparent equivalence in the overall primary ‘end’ point.
An argument used to justify the inclusion of MIs in
CREST’s primary ‘end’ point was that peri-procedural MIs
are associated with a decreased long-term survival. In
CREST, the patients who suffered a peri-procedural MI had
>3-fold higher 4-year mortality rates compared with those
who did not (19.1% vs. 6.7%, respectively; HR: 3.40; 95% CI:
1.67e6.92; p < 0.001).15 The patients who suffered a peri-
procedural MI, however, were also older (72.3  8.0 vs.
69.0  8.9 years; p ¼ 0.01) and had a higher frequency of
prior cardiovascular disease (including a history of MI,
angina, coronary insufﬁciency, intermittent claudication or
congestive heart failure; 65.8% vs. 43.3%, respectively;
p ¼ 0.02) compared with those who did not suffer a peri-
procedural MI.15 By multivariable analysis, the presence of
prior cardiovascular disease or coronary artery bypass
grafting was a strong risk factor for the occurrence of peri-
procedural MI (HR: 2.22; 95% CI: 1.13e4.35; p ¼ 0.02).15 It
is therefore not a surprise that these patients had higher 4-
year mortality rates. These high 4-year mortality rates also
raise the question of the appropriateness of any carotid
intervention in high-risk patients. As the CREST investigators
state, “for asymptomatic patients identiﬁed to be at higher
risk for MI or stroke after CEA or CAS, optimal medical
therapy may actually be the preferred option and should be
evaluated in a prospective controlled trial.”15 In addition, the
high 4-year mortality of patients after an MI (19.1%)15 was
equalled by the high 4-year mortality after a stroke (21.2%),16
further negating the argument that MIs should have been
included in CREST’s primary composite ‘end’ point.
Differences in anti-platelet treatment between CAS and
CEA patients
Patients undergoing CAS received considerably higher doses
of anti-platelet treatment in the peri-procedural period
compared with CEA patients (Table 2).1 This may have
accounted, at least in part, for the 50% lower peri-
procedural MI rates observed in the CAS compared with
the CEA patients (Table 1). CEA patients continued receiving
aspirin 325 mg day1 (or speciﬁc alternatives in the case of
intolerance to this high dose, such as aspirin 81 mg day1 orclopidogrel 75 mg day1) postoperatively indeﬁnitely (at
least for 1 year). By contrast, for CAS patients the contin-
uation of the high anti-platelet treatment (325 mg aspirin
once or twice daily for 30 days plus either 75 mg day1
clopidogrel twice daily for 4 weeks or 250 mg ticlopidine
twice daily for 4 weeks) was maintained only for 4 weeks
after the procedure (in other words, as long as the 30-day
postprocedural period described in the ‘primary ‘end’
point’). After that, the CAS patients received the same anti-
platelet treatment as the CEA patients. Possibly as a result,
although CAS was associated with 50% fewer peri-
procedural MIs compared with CEA, there were >2.5-fold
more MIs at 4 years (Table 1). Furthermore, CAS was
associated with a higher MI rate at 4 years compared with
CEA (HR: 1.44; 95% CI: 1.00e2.06; p ¼ 0.049). The 4-year
MI rate, however, was not a component of the ‘primary
‘end’ point’. Only ipsilateral strokes within 4 years after
randomisation were included in the primary ‘end’ point.
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CREST subgroup analyses
The ﬁrst CREST subgroup analysis according to symptomatic
status2 (Table 3) showed that the stroke and death rates for
all patients (symptomatic and asymptomatic) were almost
double for CAS vs CEA (HR: 1.90; p ¼ 0.005). For symp-
tomatic patients, the peri-procedural stroke and death rates
were again almost double for CAS versus CEA (HR: 1.89;
p ¼ 0.02). Asymptomatic patients undergoing CAS also had
almost double the stroke rates compared with those
undergoing CEA (HR: 1.88), but due to a wide CI, this
difference was not statistically signiﬁcant (p ¼ 0.15).2 The
ﬁnding that in symptomatic patients CAS is associated with
signiﬁcantly higher stroke and death rates compared with
CEA was reported in several other multicentre randomised
CAS versus CEA trials5,17,18 besides CREST.2 A recent meta-
analysis of these trials showed that CAS is even more
likely to cause stroke or death than CEA in patients who are
symptomatic for <2 weeks.19
CREST also reported another subgroup analysis of the
effect of gender on outcomes (Table 3).3 Although men
showed similar peri-procedural stroke rates whether under-
going CAS or CEA, women undergoing CAS had >2.5-fold
higher peri-procedural stroke rates compared with CEA. As
the CREST authors commented, “women might be at higher
risk of periprocedural stroke and death because of technical
difﬁculties related to the fact that they have smaller internal
carotid arteries than men”.3 Therefore, in females CAS was
associated with clearly inferior outcomes compared with
CEA.3 A recent, large study of 54,658 carotid revascularisa-
tion procedures (94.2% CEA; 5.8% CAS) also supports this
ﬁnding.20
In a third CREST subgroup analysis,12 it was found that
“age acted as a treatment effect modiﬁer for the primary
end-point (p ¼ 0.02)” (Table 3). CAS was associated with
similar peri-procedural stroke rates with CEA only in
patients <65 years of age.12 For patients aged 65e74 years,
CAS was associated with almost double the peri-procedural
stroke rates compared with CEA.12 Due to the wide CI, this
difference did not reach statistical signiﬁcance (p ¼ 0.08).
However, for patients 75 years, CAS was associated with
a signiﬁcant >2-fold higher peri-procedural stroke rate
compared with CEA (p ¼ 0.035).12 A similar situation was
observed at the end of the 4-year follow-up period
(Table 3). Regarding the composite primary ‘end’ point, the
risk of the two procedures was approximately equal at age
70 years, with CAS demonstrating better results for patients
<70 years and with CEA showing better results for patients
70 years.12 As the CREST investigators reported, “for
patients 70 years and older, the risk of events in CAS-treated
patients was approximately twice that for CEA-treated
patients (HR: 2.04; 95% CI: 1.48e2.82).”12 However, if the
MIs were not included, the inﬂection point for an equal
stroke risk for CAS and CEA was at 64 years, that is, 6 years
younger than the primary ‘end’ point.12
A recent report using data from the Society for Vascular
Surgery (SVS) Vascular Registry compared the outcomes of1347 CEAs and 861 CAS procedures performed on patients
aged <65 years versus 4169 CEAs and 2536 CAS procedures
performed on patients aged 65 years.21 In patients <65
years, CAS was associated with a higher incidence (but not
signiﬁcantly so) of the primary ‘end’ point consisting of 30-
day stroke, death or MI rates compared with CEA (5.23%
vs. 3.56%, respectively; p ¼ 0.065). In patients 65 years
included in the SVS Registry,21 however, CAS,when compared
with CEA, was associatedwith a signiﬁcantly higher incidence
of not only the primary ‘end’ point (30-day stroke, death or
MI rates: 7.14% vs. 4.27%, respectively; p< 0.01), but also of
death (1.97% vs. 0.91%, respectively; p < 0.01) and stroke
(4.89% vs. 2.52%, respectively; p < 0.01). In patients aged
65 years, CAS was associated with higher rates of the
composite outcome of 30-day death, stroke or MI in both
symptomatic (9.52% vs. 5.27%; p < 0.01) and asymptomatic
(5.27% vs. 3.31%; p < 0.01) subgroups.21 The conclusion
reached by the SVS Outcomes Committee was that
“compared with CEA, CAS resulted in inferior 30-day
outcomes in symptomatic and asymptomatic patients aged
65 years.These ﬁndings do not support the widespread use
of CAS in patients aged 65 years.”21Strokes after CAS and CEA
The CREST investigators recently reported that “stroke is
a more frequent complication of CAS compared to CEA. In
CREST, this greater occurrence of stroke in the CAS arm was
offset by the greater occurrence of MI in the CEA arm”.16 An
analysis of the baseline and plaque characteristics of those
patients who did suffer a stroke versus those who did not
showed that CAS patients who suffered a stroke were more
likely to be older (73.0  7.7 vs. 68.5  9.0 years, respec-
tively; p < 0.001) and symptomatic (70.8% vs. 52.3%,
respectively; p ¼ 0.01). Furthermore, patients with speciﬁc
plaque characteristics undergoing CAS were more likely to
suffer a stroke, namely those with ulcerated (54.2% vs.
36.0%, respectively; p ¼ 0.01) or eccentric plaques (70.8%
vs. 56.6%, respectively; p ¼ 0.051) and those with long
carotid lesions (20.9  7.6 vs. 17.6  8.5 mm, respectively;
p ¼ 0.01). By contrast, there was no difference in patient
and carotid plaque baseline characteristics of those
suffering a stroke in the CEA arm. Finally, the 4-year
mortality rates were almost 3-fold higher in the stroke
group compared with the stroke-free group (21.2% vs.
11.6%, respectively; HR: 2.78; 95% CI: 1.63e4.76; p value
not provided).16
CAS FOR ASYMPTOMATIC CAROTID STENOSIS
Although almost double, the stroke and death rates of
asymptomatic patients in CREST1 undergoing CAS did not
differ signiﬁcantly from those undergoing CEA (2.5%  0.6%
vs. 1.4%  0.5%, respectively; HR, 1.88; 95% CI, 0.79e4.42;
p ¼ 0.15).2 According to the AHA/ASA guideline,8 CAS might
be considered in selected asymptomatic patients, but its
effectiveness compared with current BMT alone for these
patients is not well established (Class IIb). However, it has
been proposed that current BMT alone may be the
Table 3. Summary of the results of CREST1 and its subgroup analyses.2,3,12
Study Results
CREST1
- For 2502 pts over a median follow-up period of 2.5 years, there was
no signiﬁcant difference in the estimated 4-year rates of the primary
end-point between the CAS and the CEA groups (7.2% vs 6.8%,
respectively; HR with CAS: 1.11; 95% CI: 0.81e1.51; p ¼ 0.51).
- There was no differential treatment effect with regard to the primary
end-point according to symptomatic status (p ¼ 0.84) or sex (p ¼ 0.34).
CREST subgroup analysis by symptomatic status2
- Periprocedural stroke and death rates: 4.4% vs 2.3%, for CAS vs CEA,
respectively; HR: 1.90; 95% CI: 1.21e2.98; p ¼ 0.005.
- Periprocedural stroke and death rates for symptomatic pts: 6.0%  0.9%
vs 3.2%  0.7%, for CAS vs CEA, respectively; HR: 1.89; 95% CI: 1.11e
3.21; p ¼ 0.02.
- Periprocedural stroke and death rates for asymptomatic pts:
2.5%  0.6% vs 1.4%  0.5%, for CAS vs CEA, respectively; HR: 1.88;
95% CI: 0.79e4.42; p ¼ 0.15.
CREST sub-group analysis by sex3
- Periprocedural strokes for men: 27 vs 20 events (3.7% vs 2.4%), for CAS
vs CEA, respectively; HR for CAS: 1.39; 95% CI: 0.78e2.48; p ¼ 0.26.
- Periprocedural strokes for women: 25 vs 9 events (5.5% vs 2.2%), for CAS
vs CEA, respectively; HR for CAS: 2.63; 95% CI: 1.23e5.65; p ¼ 0.013.
CREST subgroup analysis by age12
- Periprocedural strokesa in pts <65 yrs: 9 vs 8 (2.2% vs 2.1%), for CAS vs
CEA, respectively; HR for CAS: 1.10; 95% CI: 0.42e2.84; p ¼ 0.85.
- Periprocedural strokesa in pts 65e74 yrs: 20 vs 10 (3.8% vs 2.0%), for CAS
vs CEA, respectively; HR for CAS: 1.98; 95% CI: 0.93e4.23; p ¼ 0.08.
- Periprocedural strokesa in pts ‡75 yrs: 23 vs 11 (6.9% vs 3.1%), for CAS vs
CEA, respectively; HR for CAS: 2.17; 95% CI: 1.06e4.45; p ¼ 0.035.
- Stroke end-pointb in pts <65 yrs: 13 vs 16 (3.7% vs 4.5%), for CAS vs CEA,
respectively; HR for CAS 0.78; 95% CI: 0.37e1.62; p ¼ 0.50.
- Stroke end-pointb in pts 65e74 yrs: 26 vs 18 (5.1% vs 4.6%), for CAS vs
CEA, respectively; HR for CAS 1.42; 95% CI: 0.78e2.60; p ¼ 0.25.
- Stroke end-pointb in pts ‡75 yrs: 33 vs 16 (10.9% vs 4.9%), for CAS vs
CEA, respectively; HR for CAS 2.15; 95% CI: 1.19e3.91; p ¼ 0.01.
CAS: carotid artery stenting; CEA: carotid endarterectomy; HR: hazard ratio; CI: conﬁdence interval; yrs: years.
a Any stroke within the periprocedural period.
b Any stroke within the periprocedural period and 4-year postprocedural ipsilateral stroke.
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that no invasive treatment is required for the majority.22e24
Until appropriately designed trials have compared the
effectiveness of CAS versus CEA versus current BMT alone in
asymptomatic patients, it may be inappropriate to recom-
mend CAS for most of these patients.CONCLUSIONS
Although the CREST data were initially interpreted as
showing that there were no differences in outcomesbetween the two procedures,1 subsequent subgroup anal-
yses showed that CAS was associated with higher stroke
and death rates in symptomatic patients,2 females3 and
patients 65 years12 compared with CEA. If these groups
are removed, the only patients left in whom CAS was
associated with similar stroke and death rates with CEA
were asymptomatic males <65 years of age.2,3,12 However,
current BMT alone may be the treatment of choice for most
asymptomatic patients.22e24 If this concept is veriﬁed, there
may be even fewer indications for CAS. CAS may be
restricted to symptomatic patients in whom CEA is more
544 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 6 June/2013risky (e.g., surgically inaccessible carotid lesions, those with
scarred or infected necks, recurrent laryngeal nerve injury
or contralateral internal carotid artery occlusion, etc.).25,26
Importantly, the outcomes of CEA versus CAS versus
current BMT alone have not been studied in these high-risk
symptomatic patients.
Thus, current data suggest that CEA and CAS are not
equivalent for the management of symptomatic patients.
Although CAS has up until now been associated with
higher stroke and death rates compared with CEA, it is
important to emphasise that CREST used CAS technology
and indications that are now outdated. With current and
future improvements, such as better embolic protection
methods (reversal and cessation of ﬂow devices), better
stents (membrane or mesh covered) and better patient
selection, it is likely that CAS outcomes will improve and
CAS will become increasingly competitive compared with
CEA. It is also likely that the two procedures will have
a complementary role in certain patients. However, further
trials are needed to justify this assumption and to docu-
ment the equivalence or superiority of CAS to CEA in
various patient groups that will show a beneﬁt beyond
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